Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AMGN compared with SABS: revenue, margins and what each company keeps, and the suppliers and customers both name
AMGN
Amgen Inc
Change
Mkt cap
Revenue
Revenue
SABS
SAB Biotherapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
AMGN
Amgen Inc
vs
SABS
SAB Biotherapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AMGN, solid
SABS, dashed
Supply-chain overlap
Revenue flow
SABS: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only AMGN
12
PODD
Insulet
supplier
CYTK
Cytokinetics
supplier
ARWR
Arrowhead Pharmaceuticals
supplier
LGND
Ligand Pharmaceuticals
supplier
8 more · AMGN chain
›
Shared
0
No shared counterparties.
Only SABS
5
EBS
Emergent BioSolutions Canada
supplier
—
Avance Clinical PTY, Ltd ("Avance")
unlisted
supplier
—
Fortrea Holdings Inc. ("Fortrea")
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
—
Sanford Applied Biosciences
unlisted
supplier
1 more · SABS chain
›
AMGN
Amgen Inc
Change
481.50
▲
+0.63%
Mkt cap
$258.8B
Revenue
$10.4B
Q3 FY26
Revenue
$36.8B
FY25
SABS
SAB Biotherapeutics, Inc.
Change
3.05
▼
−3.97%
Regular session
Nov 5 '26
Mkt cap
$283.9M
Revenue
$114,698
Q4 FY24
Revenue
—
vs
Compare
Regular session
Nov 5 '26
AMGN
Amgen Inc
vs
SABS
SAB Biotherapeutics, Inc.
481.50
▲
+0.63%
Price
3.05
▼
−3.97%
$258.8B
Mkt cap
$283.9M
Q3 FY26
$10.4B
Revenue
$114,698
Q4 FY24
FY25
$36.8B
Revenue
—
Change
Change
AMGN
481.50
▲
+0.63%
vs
SABS
3.05
▼
−3.97%
Regular session
Nov 5 '26